Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia

Malaria Clinical Trial

Official title:

Evaluation of the Effect of Targeted Mass Drug Administration and Reactive Case Detection on Malaria Transmission and Elimination in East Hararghe Zone, Oromia, Ethiopia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04241705
• Other study ID #: 1
• Status: Recruiting
• Phase: N/A
• Start date: January 20, 2020
• Est. completion date: January 20, 2022

Study information

• Verified date: June 2020
• Source: Armauer Hansen Research Institute, Ethiopia
• Contact: Endalamaw Gadisa, PhD, MSc
• Phone: +251911868827
• Email: endalamaw.gadisa[@]ahri.gov.et
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Reactive and proactive case detection measures are widely implemented by national malaria elimination programs globally. Similarly, the Ethiopian Federal Ministry of Health decided to include reactive case detection (RCD) and targeted mass drug administration (tMDA) approaches as part of their elimination strategy, along with rigorous evaluation. This study aims to evaluate the impact on annual parasite incidence (API) and cost-effectiveness of implementing tMDA and RCD within a 100-meter radius of passively detected index case, compared with standard of care in the control arm. In addition, cross-sectional surveys will measure the change in malaria prevalence over the two-year study intervention period. The aim is to generate evidence to inform Ethiopia's national strategy for malaria elimination.

Description:

Study design: Cluster randomized controlled trial

Primary aim: To compare the effect of targeted mass drug administration (tMDA) versus reactive case detection (RCD) on reducing malaria incidence

Study site: Elimination targeted areas within East Hararghe Zones, Oromia Regional State, which is comprised of 24 woredas/districts

Cluster or unit of randomization: Kebeles will be randomized to the control, RCD or tMDA arms using simple randomization

Evaluation methods: The primary outcome measure of annual parasite incidence (API) will be obtained through routine surveillance data at all health facilities (health centers and health posts).

Secondary outcomes will be measured through cross-sectional surveys and study monitoring data:

1. Case investigation. At the time of diagnosis of the index case and enrollment of community members to the study, a short questionnaire will be administered to collect demographic data and assess malaria risk, including past malaria treatment and travel history, access to malaria interventions, occupation, etc.

2. Cross-sectional surveys. At baseline and end of the study period (year 2), cross-sectional household surveys will be conducted to assess malaria prevalence, household and individual risk factors for malaria, including access to malaria interventions. It will also assess knowledge of, attitude towards, and participation in the study intervention.

3. Longitudinal feasibility measurements: Coverage of RCD or tMDA in the target population, acceptability of RCD or tMDA in the target population, serious adverse event (SAE) reports, adherence measured by self-report and pill count, and cost data from all arms

4. Laboratory testing: The conventional rapid diagnostic test (RDT) for malaria will be used in the RCD arm. Dried blood spots (DBS) will be collected for molecular and serological testing during the cross-sectional surveys in all arms. DBS collected in incident cases as part of routine surveillance as well as during the RCD activities will also be utilized for antigen, antibody, and molecular testing. G6PD testing will be used in the RCD and tMDA arm to guide primaquine (PQ) treatment.

Sample size: To measure the primary outcome, change in incidence, 16,000 Households (HH) (16 clusters, 1,000 HH each) per arm will be included in the study. For the cross-sectional surveys, 320 randomly selected HHs per arm (16 clusters, 20HH/cluster) will be included.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48960
• Est. completion date: January 20, 2022
• Est. primary completion date: January 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

• Woreda-level: Of the 19 woredas with malaria risk, the ten woredas with the highest annual parasite incidence (API) in 2018 will be eligible for the study.

• For Kebeles:

• Kebeles in East Hararghe Zone targeted for implementation of elimination activities by the Ethiopian Federal Ministry of Health where there is ongoing PMI-supported malaria surveillance;

• Kebeles with reported API between 1 and 50;

• Kebeles in malarious districts with comparable optimization of malaria control interventions.

• For individual participants:

• All residents of the intervention study kebeles diagnosed with malaria at health facilities (index case) or reside within 100-meter radius with the index case and has NONE of the exclusion criteria listed below

• Able to provide informed written consent

Exclusion Criteria:

• For kebeles: Kebeles planning on starting for the first time or discontinuing indoor residual spraying (IRS) campaigns in the next two years.

• For individual participants:

• Children less than 6 months of age or <5 kg

• Known allergy or history of adverse reaction or chronic/congenital disease contra indicated to any of the intervention drugs: PQ, AL or CQ

• Individuals with severe malnutrition or signs of severe disease, with evidence of any organ failure or Hgb level < 8gm/dl

• Household members already covered by the intervention less or equal to one month before

In addition, the following individuals will be excluded from receiving primaquine:

• Phenotypically G6PD deficient individuals

• Pregnant women

• Lactating women breastfeeding infants less than 6 months of age or with unknown G6PD status

Related Conditions & MeSH terms

• Malaria

Intervention

Other:
• Treatment of positive individuals per national treatment guidelines
Treatment for everyone except children <6 months of age, pregnant women, women breastfeeding children <6 months of age, and women 12-49 years of age with an unknown pregnancy status: P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily) P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily) Treatment for pregnant women and women breastfeeding children <6 months of age: P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd & 3rd trimesters or breastfeeding) P. vivax cases: Chloroquine (CQ)
• Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)
Everyone who is eligible for the study except pregnant women and women breastfeeding children <6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria. Women in the first trimester of pregnancy will be treated presumptively with quinine. Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL). Again, treatment will be given without RDT for malaria.
• Optimized malaria control interventions
Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.

Locations

Country	Name	City	State
Ethiopia	Woreda 6:	Alemaya
Ethiopia	Woreda 1:	Babile
Ethiopia	Woreda 2:	Fedis
Ethiopia	Woreda 3:	Girawa
Ethiopia	Woreda 4:	Golo oda
Ethiopia	Woreda 5:	Gursum
Ethiopia	Woreda 7:	Kersa
Ethiopia	Woreda 8:	Kombolcha
Ethiopia	Woreda 9:	Kurfa chele
Ethiopia	Woreda 10:	Midega Tola

Sponsors (8)

Lead Sponsor	Collaborator
Armauer Hansen Research Institute, Ethiopia	Addis Continental Institute of Public Health, Ethiopian Federal Ministry of Health, Oromia Regional Health Bureau, Tulane University, U.S. Centers for Disease Control and Prevention, U.S. President's Malaria Initiative, United States Agency for International Development (USAID)

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in malaria annual parasite incidence (API)	The effect of RCD or tMDA will be defined as a change in malaria API among residents measured by microscopy/RDT through health centers and health posts. The malaria API will be defined as all passively detected RDT or microscopy confirmed cases over a period of 12 months, who are residents of the kebele divided by the estimated population in the intervention kebele multiplied by 1000. The primary effectiveness endpoint will therefore be API among residents of the kebele at baseline and year 2 of each intervention group of study clusters, compared with the control clusters.	Two years
Secondary	Malaria burden, measured by antigen test	Testing for pan-Plasmodium antigens aldolase and LDH will determine active infection with malaria parasite, and, if the infecting species is Pf, by the presence of HRP2 antigen (Plucinski, Herman et al. 2018).	Two years
Secondary	Malaria burden, measured by serology	Sero-prevalence will be determined using LUMINEX based multiplex assays. Age-specific sero-conversion and sero-reversion rates over the two years will be used to monitor changes in transmission and malaria exposure over time. Absence of antimalarial antibodies, particularly in children, will show the success of tMDA or RCD interventions. Antigen selection will be informed by recent studies by EPHI and CDC and a panel of antibodies characterized to indicate recent change in transmission will be included (Kerkhof, Sluydts et al. 2016).	Two years
Secondary	Malaria burden, measured by molecular testing	Real-time quantitative (qPCR) for parasite detection will be performed by targeting the 18S small rRNA gene for Pf and Pv using primer and probe sequences. Pf parasites will be quantified using standard curves generated from a serial dilution of NF54 ring stage parasites. Pv parasite quantification will be done using plasmid constructs to infer copy numbers as described before. Blood samples in RNA protect buffers will be used for extraction of RNA using the RNeasy Mini Kit (QIAGEN) for gametocyte quantification, gametocyte commitment and maturation assays, sex ratio estimation, asexual stage parasites detection, and expression level of regulators of the balance between reproduction and replication.	Two years
Secondary	Intervention coverage	To compare intervention coverage in RCD and tMDA arms. After RCD and tMDA interventions, coverage will be estimated by calculating the proportion of all enumerated household members reached in each index case event and the proportion of individuals tested and/or on treatment.	Two years
Secondary	Acceptability	To compare acceptability of RCD and tMDA. During the baseline and endline cross-sectional surveys, the household head will be asked questions about the acceptability of the RCD and tMDA interventions (self-report).	Two years
Secondary	Serious adverse events	To compare number of serious adverse events between the RCD and tMDA arms	Two years
Secondary	Adherence	To compare the adherence to antimalarials between the RCD and tMDA arms. Adherence will be measured by self-report and pill count.	Two years
Secondary	Costs	To compare the costs of RCD and tMDA. Costs will be calculated using an ingredients approach that involves enumerating both the quantity of specific inputs (e.g., hours spent, cost of treatment, number of RDTs used, etc.) and the time spent during the intervention. Quantity and time will be converted to a common monetary cost measure. Existing infrastructure and recurrent inputs that would be present in the absence of the intervention will not be included in cost analysis. The emphasis of the cost analysis is on determining the cost of RCD and tMDA alone.	Two years
Secondary	Cost-effectiveness	To assess the cost-effectiveness of RCD and tMDA relative to control. Cost-effectiveness will be measured through incident malaria cases averted as measured through the difference in malaria incidence in RCD and tMDA kebeles.	Two years
Secondary	Sensitivity and specificity of polymerase chain reaction (PCR)	To evaluate the sensitivity and specificity of PCR as compared to antigen- based multiplex testing	Two years
Secondary	Ratio of imported to locally acquired incident cases	To assess the ratio of imported to locally acquired incident cases	Two years